Orally disintegrating tablets, fast-dissolving, buccal and sublingual formulations
نویسندگان
چکیده
منابع مشابه
An Overview on fast Disintegrating Sublingual Tablets
The demand of fast disintegrating tablets has been growing during the last decade, due to the characteristics of fast disintegrating sublingual tablets for the potential emergency treatment. In terms of permeability, the sublingual area of the oral cavity (i.e, the floor of the mouth) is more permeable than the buccal (cheek) area, which in turn is more permeable than the palatal (roof) of the ...
متن کاملRisperidone Orally Disintegrating Tablets
---------------------------------------------------RECENT MAJOR CHANGES------------------------------------------------- Indications and Usage, Schizophrenia/Adolescents (1.1) 08/2007 Indications and Usage, Bipolar Mania/Pediatrics (1.2) 08/2007 Dosage and Administration, Schizophrenia/Adolescents (2.1) 08/2007 Dosage and Administration, Bipolar Mania/Pediatrics (2.2) 08/2007 -----------------...
متن کاملOrally Disintegrating Tablets: An Overview
Article history: Received on: 06/01/2014 Revised on: 22/01/2014 Accepted on: 12/02/2014 Available online: 27/02/2014 Orally disintegrating tablets (ODTs) have greatly increased dosage forms which have remarkable impact on the patient compliance especially for the pediatric, geriatric and psychiatric patients with deglutition disorders. Several technologies either conventional or patented based ...
متن کامل(rizatriptan Benzoate) Orally Disintegrating Tablets
Its empirical formula is C15H19N5•C7H6O2, representing a molecular weight of the free base of 269.4. Rizatriptan benzoate is a white to off-white, crystalline solid that is soluble in water at about 42 mg per mL (expressed as free base) at 25°C. MAXALT Tablets and MAXALT-MLT* Orally Disintegrating Tablets are available for oral administration in strengths of 5 and 10 mg (corresponding to 7.265 ...
متن کاملARICEPT Tablets and ARICEPT Orally Disintegrating Tablets (ODT). ARICEPT
----------------------------RECENT MAJOR CHANGES-------------------- Addition of new dosage strength: ARICEPT 23 mg ----------------------------INDICATIONS AND USAGE--------------------- ARICEPT is an acetylcholinesterase inhibitor indicated for the treatment of dementia of the Alzheimer’s type. Efficacy has been demonstrated in patients with mild, moderate, and severe Alzheimer’s Disease (1.0).
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Pharmaceutical Development and Technology
سال: 2018
ISSN: 1083-7450,1097-9867
DOI: 10.1080/10837450.2018.1462471